Investigation of C3435T Polymorphism in MDR1 Gene of Breast Cancer Patients

authors:

avatar Mohsen Taheri 1 , * , avatar Frouzandeh Mahjoubi 2 , avatar Ramesh Omranipour 3 , avatar Frouzandeh Fereidouni 4

Instructor, Dept of Hematology, Faculty of Medicine, Zahedan University of Medical Sciences and Health services, Zahedan, Iran and Genetics National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Assistant Prof, Dept of Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Assistant Prof of Surgery, Institute of Cancer, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Associate Prof of Pathology, Institute of Cancer, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Zahedan Journal of Research in Medical Sciences: Vol.11, issue 3; e94384
published online: November 20, 2009
article type: Research Article
received: May 04, 2009
accepted: July 01, 2009

how to cite: Taheri M, Mahjoubi F, Omranipour R, Fereidouni F. Investigation of C3435T Polymorphism in MDR1 Gene of Breast Cancer Patients. Zahedan J Res Med Sci. 2009;11(3):e94384. 

Abstract

Background: Resistance to drugs with different structure and function is a great obstacle to the successful treatment of breast cancer. A well-known mechanism responsible for drug resistance is over-expression of ABC-transporter genes such as MDR1. MDR1 gene polymorphisms may result in drug resistance. In this study we investigated the possible correlation between MDR1 gene C3435T polymorphism and clinicopathologic findings and response to treatment in Iranian breast cancer patients. Materials and Methods: In this descriptive study we investigated C3435T polymorphism of MDR1 gene in 54 breast cancer patients admitted to Imam Khomeini Hospital of Tehran and 40 individuals without history of breast cancer by PCR-RFLP technique during 2006-2008. Association of this polymorphism with response to treatment and clinicopathologic characteristics were also investigated. Data were analyzed using Chi-Square test and SPSS software. P values<0.05 were considered to be statistically significant. Results: In patient group frequencies of genotypes were 18% for CC, 56%for CT and %26 for TT whereas in control group frequencies of genotypes were %23 for CC, %50 for CT and %27 for TT. There was no significant difference in frequency of C3435T polymorphism between breast cancer patients and healthy controls. Frequency of C3435T polymorphism between responders and non-responders was not significant. Conclusions: It seems that there is no correlation between C3435T polymorphism of MDR1 gene and response to treatment, clinical findings and pathologic characteristics of breast cancer. So the role of C3435T polymorphism in response to treatment is still controversial.

Fulltext

 The full text of this article is available on the PDF file.

 

References

  • 1.

    The References of this article are available on the PDF file.